OTX008, a selective small molecule Gal1 inhibitor, has been preclinically tested and shown to inhibit tumor growth in human glioblastoma and ovarian cancer [99], head and neck squamous carcinoma [100], and hepatocellular carcinoma [101]. The gene discussed is LGALS1; the disease is ovarian carcinoma.